Clinical research in the area of fatty acid metabolism is increasingly recognizing the link between diet and chronic inflammatory diseases. The pro-inflammatory and anti-inflammatory forces at work in the human body are related to Omega-3 vs. Omega-6 balances in the diet. Diet plays a major role in the fatty acids available for cells, blood, plasma and tissue.
Research at ALP is focused on fatty liver disease and its connection to most inflammatory diseases. In addition, published research on Omega-3 consumption as a possible treatment for fatty liver disease is on the rise and results are promising, but additional research is needed and recommended dosage amounts have not been established.
The human body absorbs long-chain Omega-3 fatty acids in the small and large intestines. There is also a difference in how natural triglycerides vs. ethyl esters (the majority of Omega-3s available) are absorbed. The need for a natural triglyceride enteric coated form Omega-3 to maximize absorption and bioavailability is clear.
Consumers are wasting money on many Omega-3 formulations that do not maximize absorption and bioavailability. ALP High 3 is the Omega-3 formulation based on the state of the art medical science that maximizes absorption and bioavailability and therefore minimizes the costs of the Omega-3s that are incorporated into the human body, giving consumers more Omega-3 value for their money.
A quick review of the peer reviewed scientific literature using Google Scholar reveals the growing body of scientific evidence of the connection between omega-3 and omega-6 levels and the epidemic of chronic inflammatory diseases:
Heart Disease+Omega 3/Omega 6 Ratios+Arachidonic Acid
Cancer+Omega 3/Omega 6 Ratios+Arachidonic Acid
Alzheimer+Omega 3/Omega 6 Ratios+Arachidonic Acid
Arthritis+Omega 3/Omega 6 Ratios+Arachidonic Acid
Fatty Liver Disease+Omega 3/Omega 6 Ratios+Arachidonic Acid
Chronic Inflammatory Disease+Omega 3/Omega 6 Ratios+Arachidonic Acid